La Jolla Pharmaceutical Company (LJPC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:La Jolla Pharmaceutical Company (LJPC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10073
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company’s major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its clinical-stage investigational product includes LJPC-401, a formulation of synthetic human hepcidin intended for the treatment of iron overload, such as hereditary hemochromatosis, sickle cell disease, beta thalassemia and myelodysplastic syndrome. The company distributes its products through a network of specialty distributors to hospitals across the US. La Jolla is headquartered in San Diego, California, the US.

La Jolla Pharmaceutical Company (LJPC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
Licensing Agreements 15
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15
IURTC Enters into Licensing Agreement with La Jolla Pharma 16
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17
La Jolla Pharma Enters into Licensing Agreement with George Washington University 18
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19
Equity Offering 20
La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharmaceutical Company – Key Competitors 30
La Jolla Pharmaceutical Company – Key Employees 31
La Jolla Pharmaceutical Company – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Oct 24, 2018: La Jolla Pharmaceutical Company Reports Financial Results for the Three and Nine Months Ended September 30, 2018 33
Aug 08, 2018: La Jolla Pharmaceutical company announces financial results for the three and six months ended June 30, 2018 and recent corporate progress 34
May 10, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress 35
Feb 22, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress 37
Oct 26, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 38
Jul 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 39
Apr 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 40
Feb 23, 2017: La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress 41
Product News 42
09/13/2017: Researchers Develop New Strategy to Target KRAS Mutant Cancer 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15
IURTC Enters into Licensing Agreement with La Jolla Pharma 16
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17
La Jolla Pharma Enters into Licensing Agreement with George Washington University 18
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19
La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharmaceutical Company, Key Competitors 30
La Jolla Pharmaceutical Company, Key Employees 31
La Jolla Pharmaceutical Company, Subsidiaries 32

List of Figures
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[La Jolla Pharmaceutical Company (LJPC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • United Supermarkets LLC:戦略・SWOT・企業財務分析
    United Supermarkets LLC - Strategy, SWOT and Corporate Finance Report Summary United Supermarkets LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Litha Healthcare Group Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Litha Healthcare Group Ltd (Litha Healthcare), formerly Myriad Medical Holdings Limited, a subsidiary of Endo International plc is a healthcare company that provides its services to public and private hospitals, pharmacies, general, allied practitioners, and government healthcare programmes. …
  • MMRGlobal Inc (MMRF):企業の財務・戦略的SWOT分析
    MMRGlobal Inc (MMRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SunTrust Banks Inc:企業の戦略・SWOT・財務情報
    SunTrust Banks Inc - Strategy, SWOT and Corporate Finance Report Summary SunTrust Banks Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Larsen & Toubro Ltd (LT):企業の財務・戦略的SWOT分析
    Larsen & Toubro Ltd (LT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • PendoPharm Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PendoPharm Inc (PendoPharm), a subsidiary of Pharmascience Inc, is a healthcare company that provides production and commercialization of a wide range of drugs. The company provides products such as spans prescription drugs, over-the-counter and behind-the-counter products, among others. Its …
  • LG International Corp:企業のM&A・事業提携・投資動向
    LG International Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LG International Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • W. L. Gore & Associates Inc:企業の製品パイプライン分析
    Summary W. L. Gore & Associates Inc (Gore) is a materials science company serving diverse industries. Its product portfolio includes consumer products, cables, electronic components, fabrics, fibers, medical, pharmaceutical, sealing and vents. The company develops products for medical implants; fabr …
  • 88 Energy Ltd (88E):企業の財務・戦略的SWOT分析
    Summary 88 Energy Ltd (88 Energy), formerly Tangiers Petroleum Ltd, is an exploration and production company that develops oil-rich provinces. The company offers discovery, exploration and development of onshore oil projects. It has oil and gas assets in Morocco and Australia. 88 Energy’s Morocco pr …
  • Rex International Holding Ltd (5WH):企業の財務・戦略的SWOT分析
    Summary Rex International Holding Ltd (Rex International) formerly Rex International Holding Pte Ltd is an independent exploration and production oil company. The company develops oil and gas properties across Singapore. It operates substantial oil and gas exploration concessions in the UAE, Oman, N …
  • HSH Nordbank AG:企業のM&A・事業提携・投資動向
    HSH Nordbank AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's HSH Nordbank AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Medistim ASA (MEDI):企業の財務・戦略的SWOT分析
    Summary MediStim ASA (MediStim) is a medical device company that manufactures and markets medical products for cardiac, vascular and transplant surgeries. The company’s products include MiraQ cardiac, MiraQ vascular, MiraQ ultimate system, imaging probes, flow probes, VeriQ C and VeriQ systems. Its …
  • Steel Connect Inc (STCN):企業の財務・戦略的SWOT分析
    Steel Connect Inc (STCN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tenneco Inc (TEN):企業の財務・戦略的SWOT分析
    Tenneco Inc (TEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Glythera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Glythera Ltd (Glythera) is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprie …
  • Medworxx Inc-医療機器分野:企業M&A・提携分析
    Summary Medworxx Inc (Medworxx), a subsidiary of Aptean Inc is an information technology solution provider that offers software solutions for patient flow, compliance, and education. The company’s software products include patient throughput review software, clinical criteria software, forms and ass …
  • J Uriach Y Compania SA-製薬・医療分野:企業M&A・提携分析
    Summary J Uriach Y Compania SA (Uriach) is a pharmaceutical company that offers food supplements, cosmetics and OTC products. It also researches, develops and manufactures active ingredients for the pharmaceutical market. Uriach provides antiflatulents, antifungals, mineral supplements and antiplate …
  • G M Breweries Ltd:企業の戦略・SWOT・財務分析
    G M Breweries Ltd - Strategy, SWOT and Corporate Finance Report Summary G M Breweries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Metso Corporation:企業の戦略・SWOT・財務分析
    Metso Corporation - Strategy, SWOT and Corporate Finance Report Summary Metso Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Icelandair Group:企業の戦略・SWOT・財務情報
    Icelandair Group - Strategy, SWOT and Corporate Finance Report Summary Icelandair Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆